Related Articles
Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer
Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: A phase II study
First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non‑small cell lung cancer
Efficacy of lapatinib combined with capecitabine in patients with HER2‑positive metastatic breast cancer in a real‑world study